Loss of heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer

Cancer Prevention Research

Volumn 5, Issue 9, 2012, Pages 1081-1089

  Zhang, Lewei ^b   Poh, Catherine F ^a,b   Williams, Michele ^a,b   Laronde, Denise M ^a,b   Berean, Ken ^b   Gardner, Pamela J ^a   Jiang, Huijun ^a   Wu, Lang ^b   Lee, J Jack ^d   Rosin, Miriam P ^a,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DYSPLASIA; FEMALE; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; VALIDATION STUDY;

DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE;

EID: 84866182142     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0173     Document Type: Article

References (29)

1. Ferlay J SH, Forman D, Mathers CD, Parkin D. Cancer incidence and mortality Worldwide. In: GLOBOCAN: IARC Cancer Base; 2008.
2. Silverman S Jr, Gorsky M, Kaugars GE. Leukoplakia, dysplasia, and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:117.
3. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92. (Pubitemid 26170679)
4. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-5. (Pubitemid 26191956)
5. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702-10. (Pubitemid 30305062)
6. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med 2001;344:1323-6. (Pubitemid 32372968)
7. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357-62. (Pubitemid 30111451)
8. Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC, et al. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 2002;62:5295-300. (Pubitemid 35024605)
9. Serrano M, Blasco MA. Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 2007;8:715-22. (Pubitemid 47312829)
10. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. (Pubitemid 26072233)
11. The R Project for statistical computing. (2008). R version 2.13.1. [cited 2011 Jun 30]. Available from: http://www.r-project.org.
12. Axell T, Pindborg JJ, Smith CJ, vanderWaal I. Oral white lesions with special reference to precancerous and tobacco related lesions: Conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. J Oral Pathol Med 1996;25:49-54.
13. Wrangle JM, Khuri FR. Chemoprevention of squamous cell carcinoma of the head and neck. Curr Opin Oncol 2007;19:180-7. (Pubitemid 46597475)
14. Klass CM, Shin DM. Current status and future perspectives of chemoprevention in head and neck cancer. Curr Cancer Drug Tar 2007;7:623-32.
15. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 2009;27:599-604.
16. Lippman SM, Lee JJ. Reducing the "risk" of chemoprevention: defining and targeting high risk - 2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 2006;66:2893-903.
17. Serrano M, Lee HW, Chin L, CordonCardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37. (Pubitemid 26116804)
18. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15. (Pubitemid 39551658)
19. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006;7:667-77. (Pubitemid 44268212)
20. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-75. (Pubitemid 44572384)
21. Rossi DJ, Jamieson CHM, Weissman IL. Stem cells and the pathways to aging and cancer. Cell 2008;132:681-96. (Pubitemid 351253688)
22. Dimri GP. What has senescence got to do with cancer? Cancer Cell 2005;7:505-12. (Pubitemid 40799244)
23. Peters G. An INKlination for epigenetic control of senescence. Nat Struct Mol Biol 2008;15:1133-4.
24. Lee JJ, Hung HC, Cheng YG, Chen YJ, Chiang CP, Liu BY, et al. Carcinoma and dysplasia in oral leukoplakias in Taiwan: prevalence and risk factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:472-80.
25. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 1998;34:275-6.
26. Hogewind WF, van der Kwast WA, van der Waal I. Oral leukoplakia, with emphasis on malignant transformation. A follow-up study of 46 patients. J Craniomaxillofac Surg 1989;17:128-33. (Pubitemid 19108980)
27. Silverman S, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: A follow-up study of 257 patients. Cancer 1984;53:563-8. (Pubitemid 14182737)
28. The Erlotinib prevention of oral cancer study. [cited 2011 Jun 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT00402779.
29. The cetuximab for treatment of high-risk premalignant upper aerodigestive lesions trial. [cited 2011 Jun 30]. Available from: http://clinicaltrials.gov/ ct2/show/NCT00524017